Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Atlas tests single-asset VC model with $18M in Arteaus to develop Lilly migraine molecule

This article was originally published in Scrip

Executive Summary

The first funded example of Atlas Venture Development Corp's strategy of setting up virtual companies to develop single drug asset is Arteaus Therapeutics. The Cambridge, Massachusetts start-up, founded in June 2011, has attracted $18 million in financing from Atlas Venture and from OrbiMed Advisors to develop a Phase I antibody licensed from Eli Lilly to prevent migraines. The antibody product targets the calcitonin gene-related peptide (CGRP) receptor.


Related Content

Finance Watch: Arteaus Comes Full Circle As Investors Monetize Emgality Royalties


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts